Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Kwee Yong, PhD, Samantha Hinsley, Holger W. Auner, MD PhD, Debbie Sherratt, Ruth Mary De Tute, BSc,MSc, Sarah Brown, Louise Flanagan, Cathy Williams, Jamie Cavenagh, Martin F Kaiser, MD, Neil Rabin, Karthik Ramasamy, Mamta Garg, MD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Gareth J. Morgan, MD PhD, Faith E. Davies, MD, Roger G Owen, MD

Blood (2017) 130 (Supplement 1): 835.

https://doi.org/10.1182/blood.V130.Suppl_1.835.835

Published: 2017

Journal Articles

Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the 'Myeloma UK Seven' Biomarker Trial

Amy L Sherborne, PhD, Vallari Shah, MBBS, Andrew Hall, Katrina Walker, Sidra Ellis, Farzana Begum, David C Johnson, James Croft, BSc, MBBS, MRCP, Jack Kendall, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Lilit Atanesyan, Suvi Savola, Louise Flanagan, Anjan Thakurta, PhD, Mamta Garg, MD, Gordon Cook, MD PhD, Kevin Boyd, Sarah Brown, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 1851.

https://doi.org/10.1182/blood.V130.Suppl_1.1851.1851

Published: 2017

Journal Articles

Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial

Amy L Sherborne, PhD, Vallari Shah, MBBS, Sidra Ellis, Farzana Begum, Jack Kendall, David C Johnson, Roger G Owen, MD, Mark T Drayson, MD PhD, Louise Flanagan, Debbie Sherratt, Walter M Gregory, PhD, Graham Jackson, MDPhD, Guy Pratt, MD FRCP, FRCPath, Gordon Cook, MD PhD, Samantha Hinsley, Sarah Brown, Matthew W Jenner, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 1767.

https://doi.org/10.1182/blood.V130.Suppl_1.1767.1767

Published: 2017

Journal Articles

Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study)

Blood (2016) 128 (22): 207.

https://doi.org/10.1182/blood.V128.22.207.207

Published: 2016

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Kwee L Yong, MBChB, PhD, Sarah Brown, Samantha Hinsley, Louise Flanagan, Neil Rabin, MB,BS, PhD, Karthik Ramasamy, Jamie Cavenagh, Roger G Owen, Martin F Kaiser, MD, Eric Low, Catherine Williams

Blood (2015) 126 (23): 1840.

https://doi.org/10.1182/blood.V126.23.1840.1840

Published: 2015

Journal Articles

Velcade, Thalidomide, Dexamethasone and Panobinostat (VTD-P) for Patients with Relapsed and Relapsed/ Refractory Myeloma: Preliminary Results of the Muk-Six Phase I/IIa Trial

Rakesh Popat, Sarah Brown, PhD, Louise M Flanagan, PhD, James D. Cavenagh, MD

Blood (2014) 124 (21): 4766.

https://doi.org/10.1182/blood.V124.21.4766.4766

Published: 2014

Journal Articles

Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma

Stephen A Schey, MD, Kwee L Yong, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, Faith E Davies, MD, Gareth J Morgan, MD PhD, James D. Cavenagh, MD, Gordon Cook, MD, PhD, Mark Cook, Avie-Lee Coney, Sarah Brown, PhD, Louise M Flanagan, PhD, Walter Gregory, PhD, Jim Cavet, FRCPath

Blood (2013) 122 (21): 286.

https://doi.org/10.1182/blood.V122.21.286.286

Published: 2013

NARROW

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the 'Myeloma UK Seven' Biomarker Trial

Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial

Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study)

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Velcade, Thalidomide, Dexamethasone and Panobinostat (VTD-P) for Patients with Relapsed and Relapsed/ Refractory Myeloma: Preliminary Results of the Muk-Six Phase I/IIa Trial

Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the 'Myeloma UK Seven' Biomarker Trial

Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial

Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study)

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Velcade, Thalidomide, Dexamethasone and Panobinostat (VTD-P) for Patients with Relapsed and Relapsed/ Refractory Myeloma: Preliminary Results of the Muk-Six Phase I/IIa Trial

Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only